Systemic administration of a recombinant adenovirus encoding a HSA-angiostatin kringle 1-3 conjugate inhibits MDA-MB-231 tumor growth and metastasis in a transgenic model of spontaneous eye cancer

Molecular Therapy

Volumn 7, Issue 2, 2003, Pages 174-184

  Bouquet, C ^a   Frau, E ^a   Opolon, P ^a   Connault, E ^a   Abitbol, M ^b   Griscelli, F ^a   Yeh, P ^a,c   Perricaudet, M ^a  

^a CNRS   (France)

^b CERTO   (France)

^c Gencell   (France)

Author keywords

Adenovirus; Angiostatin; Antiangiogenesis; HSA conjugate; Ocular tumor; Systemic gene therapy; Transgenic mice; TRP 1

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; HUMAN SERUM ALBUMIN; TYROSINASE RELATED PROTEIN 1; VIRUS FUSION PROTEIN;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER GRAFT; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; EYE CANCER; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MOUSE; NEWBORN; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; PROTEIN DOMAIN; SEQUENCE TAGGED SITE; SIMIAN VIRUS 40; SURVIVAL TIME; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0037302521     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00057-6     Document Type: Article

References (44)

1. Folkman, J. (1995). Clinical applications of research on angiogenesis. N. Engl. J. Med. 333: 1757-1763.
2. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
3. Webb, C. P., and Vande Woude, G. G. (2000). Genes that regulate metastasis and angiogenesis. J. Neuro-Oncol. 50: 71-87.
4. O'Reilly, M. S., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
5. Kamphaus, G. D., et al. (2000). Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275: 1209-1215.
6. O'Reilly, M. S., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
7. Gately, S., et al. (1996). Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56: 4887-4890.
8. Westphal, J. R., et al. (2000). Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int. J. Cancer 86: 760-767.
9. Claesson-Welsh, L., et al. (1998). Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad Sci. USA 95: 5579-5583.
10. Cao, Y., et al. (1996). Kringle domains of human angiostatin. J. Biol. Chem. 271: 29461-29467.
11. Moser, T. L., et al. (1999). Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96: 2811-2816.
12. Tarui, T., Miles, L. A., and Takada, Y. (2001). Specific interaction of angiostatin with integrin αVβ3 in endothelial cells. J. Biol. Chem. 276: 39562-39568.
13. O'Reilly, M. S., et al. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689-692.
14. Kirsch, M., et al. (1998). Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 58: 4654-4659.
15. Kong, H. L., and Crystal, R. G. (1998). Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90: 273-286.
16. Feldman, A. L., and Libutti, S. K. (2000). Progress in antiangiogenic gene therapy of cancer. Cancer 89: 1181-1194.
17. Chen, Q. R., et al. (1999). Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59: 3308-3312.
18. Tanaka, T., et al. (1998). Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58: 3362-3369.
19. Nguyen, J. T., et al. (1998). Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58: 5673-5677.
20. Kuo, C. J., et al. (2001). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98: 4605-4610.
21. Benihoud, K., Yeh, P., and Perricaudet, M. (1999). Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10: 440-447.
22. Griscelli, F., et al. (1998). Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad Sci. USA 95: 6367-6372.
23. Griscelli, F., et al. (2000). Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA 97: 6698-6703.
24. MacDonald, N. J., et al. (1999). The tumor suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem. Biophys. Res. Commun. 264: 469-477.
25. Capon, D. J., et al. (1989). Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531.
26. Yeh, P., et al. (1992). Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad Sci. USA 89: 1904-1908.
27. Carter, D. C., and Ho, J. X. (1994). Structure of serum albumin. Adv. Protein Chem. 45: 153-203.
28. Stehle, G., et al. (1999). Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate. Anti-Cancer Drugs 10: 785-790.
29. Penna, D., Schmidt, A., and Beermann, F. (1998). Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1/SV40T antigen transgenic mice. Oncogene 17: 2601-2607.
30. Joe, Y. A., et al. (1999). Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int. J. Cancer 82: 694-699.
31. Palmiter, R. D., et al. (1991). Heterologous introns can enhance expression of transgenes in mice. Proc. Natl. Acad Sci. USA 88: 478-482.
32. Yew, N. S., et al. (1997). Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum. Gene Ther. 8: 575-584.
33. Pecceu, F., et al. (1991). Human interleukin 1 beta fused to the human growth hormone signal peptide is N-glycosylated and secreted by Chinese hamster ovary cells. Gene 97: 25 3-258.
34. Bergers, G., et al. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
35. Beecken, W. D. C., et al. (2001). Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Cancer Inst. 93: 382-387.
36. Gyorffy, S., Palmer, K., and Gauldie, J. (2001). Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am. J. Pathol. 159: 1137-1147.
37. Sacco, M. G., et al. (2000). Liposome-delivered angiostatin strongly inhibits tumor growth and metastasization in a transgenic model of spontaneous breast cancer. Cancer Res. 60: 2660-2665.
38. Sacco, M. G., et al. (2001). Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther. 8: 67-70.
39. Rapoport, S. I. (1976). Blood-Brain Barrier. Physiology and Medicine. Raven Press, New York.
40. Cunha-Vaz, J. G. (1980). NATO Advanced Study Institutes Series, Vol. 32, The Blood Retina Barriers. Plenum Press, New York.
41. Pino, R. M. (1985). Restriction to endogenous plasma protein by a fenestrated capillary endothelium: an ultrastructural immunocytochemical study of the choriocapillary endothelium. Am. J. Anat. 172: 279-290.
42. Crouzet, J., et al. (1997). Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad Sci. USA 94: 1414-1419.
43. Ades, E. W., et al. (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99: 683-690.
44. Fallaux, F. J., et al. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early region-1 deleted adenoviral vectors. Hum. Gene Ther. 7: 215-222.